AVROBIO, Inc. Stock price

Equities

AVRO

US05455M1009

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
1.29 USD -0.77% Intraday chart for AVROBIO, Inc. -0.77% -5.15%
Sales 2024 * - Sales 2025 * - Capitalization 57.87M
Net income 2024 * -77M Net income 2025 * -46M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-1.97 x
P/E ratio 2025 *
-2.93 x
Employees 78
Yield 2024 *
-
Yield 2025 *
-
Free-Float 2.62%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.77%
1 week-0.77%
Current month-1.53%
3 months-0.77%
6 months-16.77%
Current year-5.15%
More quotes
1 week
1.20
Extreme 1.2
1.31
1 month
1.20
Extreme 1.2
1.36
Current year
1.01
Extreme 1.01
1.52
1 year
0.57
Extreme 0.57
1.70
3 years
0.56
Extreme 0.56
13.22
5 years
0.56
Extreme 0.56
29.32
10 years
0.56
Extreme 0.56
53.70
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 19-01-01
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 63 18-06-19
Director/Board Member 62 17-12-31
Chairman 49 16-01-31
More insiders
Date Price Change Volume
24-03-18 1.29 -0.77% 301,725
24-03-15 1.3 +2.36% 493,543
24-03-14 1.27 -1.55% 177,195
24-03-13 1.29 +0.78% 176,659
24-03-12 1.28 -1.54% 112,495

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
AVROBIO, Inc. is a clinical-stage gene therapy company. The Company is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The Company is focusing on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies. Its pipeline is comprised of various HSC gene therapy programs, which include AVR-RD-02 for the treatment of Gaucher disease type 1 and type 3; AVR-RD-05 for the treatment of neuronopathic mucopolysaccharidosis type II (MPS-II) or Hunter syndrome; and AVR-RD-03 for the treatment of Pompe disease.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.29 USD
Average target price
2 USD
Spread / Average Target
+55.04%
Consensus
  1. Stock
  2. Equities
  3. Stock AVROBIO, Inc. - Nasdaq